FOR IMMEDIATE RELEASE
Thursday, May 14, 2020
Dr. Bright’s whistleblower complaint alleges that he was fired after voicing concerns about the effectiveness of hydroxychloroquine as a treatment for COVID-19. The drug has been described by President Trump as “one of the biggest game changers in the history of medicine,” and Greg Gianforte has invested in two pharmaceutical companies that manufacture the drug, positioning himself to profit and creating a potential conflict of interest during today’s hearing.
On March 19th – the same day President Trump first touted hydroxychloroquine during his daily briefings – Gianforte invested in Sanofi, a “major manufacturer” of hydroxychloroquine. Gianforte also invested in Novartis, another major hydroxychloroquine manufacturer. Novartis stock is up over 13% since Gianforte purchased the stock, and Sanofi is up almost 19%.
“While tens of thousands of Montanans were being laid off, Greg Gianforte was profiting off of the pandemic,” said MDP Executive Director Sandi Luckey. “Gianforte’s financial investments present a clear conflict of interest for today’s hearing. How can Montanans trust him to speak for them when he’s focused on his own pocketbook?”
Share this Post